LONGO, FRANCESCO
LONGO, FRANCESCO
Dipartimento di Scienze mediche
Age-dependent dopamine transporter dysfunction and Serine129 phospho-α-synuclein overload in G2019S LRRK2 mice
2017 Longo, Francesco; Mercatelli, Daniela; Novello, Salvatore; Arcuri, Ludovico; Brugnoli, Alberto; Vincenzi, Fabrizio; Russo, Isabella; Berti, Giulia; Mabrouk, Omar Sharif; Kennedy, Robert T; Shimshek, Derya R; Varani, Katia; Bubacco, Luigi; Greggio, Elisa; Morari, Michele
Altered motor phenotype and dopamine transmission associated with mutations of the parkinsonian gene LRRK2
2015 Longo, Francesco
D-Aspartate oxidase influences glutamatergic system homeostasis in mammalian brain
2015 Cristino, Luigia; Luongo, Livio; Squillace, Marta; Paolone, Giovanna; Mango, Dalila; Piccinin, Sonia; Zianni, Elisa; Imperatore, Roberta; Iannotta, Monica; Longo, Francesco; Errico, Francesco; Vescovi, Angelo Luigi; Morari, Michele; Maione, Sabatino; Gardoni, Fabrizio; Nisticò, Robert; Usiello, Alessandro
Genetic and pharmacological evidence that endogenous nociceptin/orphanin FQ contributes to dopamine cell loss in Parkinson's disease
2016 Arcuri, Ludovico; Viaro, Riccardo; Bido, Simone; Longo, Francesco; Calcagno, Mariangela; Fernagut, Pierre Olivier; Zaveri, Nurulain T.; Calo', Girolamo; Bezard, Erwan; Morari, Michele
Genetic and pharmacological evidence that G2019S LRRK2 confers a hyperkinetic phenotype, resistant to motor decline associated with aging
2014 Longo, Francesco; I., Russo; D. R., Shimshek; E., Greggio; Morari, Michele
L-DOPA promotes striatal dopamine release through D1 receptors and reversal of dopamine transporter
2021 Viaro, R.; Longo, F.; Vincenzi, F.; Varani, K.; Morari, M.
Leucine-rich repeat kinase 2 (LRRK2) inhibitors differentially modulate glutamate release and Serine935 LRRK2 phosphorylation in striatal and cerebrocortical synaptosomes
2019 Mercatelli, D.; Bolognesi, P.; Frassineti, M.; Pisano, C. A.; Longo, F.; Shimshek, D. R.; Morari, M.
LRRK2 kinase activity regulates synaptic vesicle trafficking and neurotransmitter release through modulation of LRRK2 macro-molecular complex
file con accesso da definire2014 M. D., Cirnaru; A., Marte; E., Belluzzi; I., Russo; M., Gabrielli; Longo, Francesco; Arcuri, Ludovico; L., Murru; L., Bubacco; M., Matteoli; E., Fedele; C., Sala; M., Passafaro; Morari, Michele; E., Greggio; F., Onofri; G., Piccoli
Protein Kinase C β: a New Target Therapy to Prevent the Long-Term Atypical Antipsychotics-Induced Weight-Gain.
file con accesso da definire2017 Rimessi, Alessandro; Pavan, C; Ioannidi, E; Nigro, F; Morganti, Claudia; Brugnoli, Alberto; Longo, Francesco; Gardin, C; Ferroni, Letizia; Morari, Michele; Vindigni, V; Zavan, B; Pinton, Paolo
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| Age-dependent dopamine transporter dysfunction and Serine129 phospho-α-synuclein overload in G2019S LRRK2 mice | 2017 | Longo, Francesco; Mercatelli, Daniela; Novello, Salvatore; Arcuri, Ludovico; Brugnoli, Alberto; V...incenzi, Fabrizio; Russo, Isabella; Berti, Giulia; Mabrouk, Omar Sharif; Kennedy, Robert T; Shimshek, Derya R; Varani, Katia; Bubacco, Luigi; Greggio, Elisa; Morari, Michele | |
| Altered motor phenotype and dopamine transmission associated with mutations of the parkinsonian gene LRRK2 | 2015 | Longo, Francesco | |
| D-Aspartate oxidase influences glutamatergic system homeostasis in mammalian brain | 2015 | Cristino, Luigia; Luongo, Livio; Squillace, Marta; Paolone, Giovanna; Mango, Dalila; Piccinin, So...nia; Zianni, Elisa; Imperatore, Roberta; Iannotta, Monica; Longo, Francesco; Errico, Francesco; Vescovi, Angelo Luigi; Morari, Michele; Maione, Sabatino; Gardoni, Fabrizio; Nisticò, Robert; Usiello, Alessandro | |
| Genetic and pharmacological evidence that endogenous nociceptin/orphanin FQ contributes to dopamine cell loss in Parkinson's disease | 2016 | Arcuri, Ludovico; Viaro, Riccardo; Bido, Simone; Longo, Francesco; Calcagno, Mariangela; Fernagut..., Pierre Olivier; Zaveri, Nurulain T.; Calo', Girolamo; Bezard, Erwan; Morari, Michele | |
| Genetic and pharmacological evidence that G2019S LRRK2 confers a hyperkinetic phenotype, resistant to motor decline associated with aging | 2014 | Longo, Francesco; I., Russo; D. R., Shimshek; E., Greggio; Morari, Michele | |
| L-DOPA promotes striatal dopamine release through D1 receptors and reversal of dopamine transporter | 2021 | Viaro, R.; Longo, F.; Vincenzi, F.; Varani, K.; Morari, M. | |
| Leucine-rich repeat kinase 2 (LRRK2) inhibitors differentially modulate glutamate release and Serine935 LRRK2 phosphorylation in striatal and cerebrocortical synaptosomes | 2019 | Mercatelli, D.; Bolognesi, P.; Frassineti, M.; Pisano, C. A.; Longo, F.; Shimshek, D. R.; Morari, M. | |
| LRRK2 kinase activity regulates synaptic vesicle trafficking and neurotransmitter release through modulation of LRRK2 macro-molecular complex | 2014 | M. D., Cirnaru; A., Marte; E., Belluzzi; I., Russo; M., Gabrielli; Longo, Francesco; Arcuri, Ludo...vico; L., Murru; L., Bubacco; M., Matteoli; E., Fedele; C., Sala; M., Passafaro; Morari, Michele; E., Greggio; F., Onofri; G., Piccoli | file con accesso da definire |
| Protein Kinase C β: a New Target Therapy to Prevent the Long-Term Atypical Antipsychotics-Induced Weight-Gain. | 2017 | Rimessi, Alessandro; Pavan, C; Ioannidi, E; Nigro, F; Morganti, Claudia; Brugnoli, Alberto; Longo..., Francesco; Gardin, C; Ferroni, Letizia; Morari, Michele; Vindigni, V; Zavan, B; Pinton, Paolo | file con accesso da definire |